Nasopharyngeal carcinoma (NPC) is prevalent in Southeast Asia. Radiotherapy can control early stage NPC effectively. However, for patients with locoregionally advanced NPC, which has higher rates of locoregional relapse and distant metastasis, radiotherapy alone can only achieve a 5year survival rate of about 50% . As a result, to improve the treatment efficacy for 窑Original Article窑 551
locoregionally advanced NPC, various phase III clinical trials on treatment modalities combining radiotherapy and chemotherapy have been launched since the 1990s, and concurrent chemoradiation therapy (CCRT) was finally defined as the standard treatment strategy for patients with locoregionally advanced NPC [16] . To improve treatment outcomes further, neoadjuvant chemotherapy combined with CCRT gradually became the focus of clinical research. Many phase III clinical trials from western countries have proved that compared with the PF [ciplatin (DDP) + 5fluorouracil (5Fu)] chemotherapy regimen, neoadjuvant chemotherapy adding taxanes to the PF regimen (TPF regimen) could significantly improve treatment outcomes [79] for patients with head and neck squamous cell carcinoma. However, there have not been any reports on the TPF regimen applied to Chinese patients. Hence in early 2007, investigators at Fudan University Shanghai Cancer Center carried out 2 prospective phase II clinical trials on patients with locoregionally advanced stageIII and IV (AB) NPC, to evaluate the efficacy and safety of neoadjuvant chemotherapy of the TPF regimen combined with CCRT. This paper will give a preliminary report on the toxicity and shortterm treatment outcomes of this treatment modality.
Patients that met the following criteria were enrolled: (1) age > 18 years and < 70 years; (2) pathology proven to be World Health Organization (WHO) type II/III NPC; (3) stage III/IV (AB) according to the 2002 American Joint Committee on Cancer (AJCC) staging criteria; (4) no distant metastasis; (5) expected lifespan of at least 6 months; (6) Karnofsky Performance Scale (KPS) score was more than 70; (7) Neutrophil count > 2 × 10 9 /L and platelet count > 100 × 10 9 /L before treatment; (8) Bilirubin < 1.5 mg/dL, AST/ALT < 2 times the upper limits of normal, serum creatinine < 1.5 mg/dL, creatinine clearance rate > 50 mL/min before treatment; and (9) informed consent was signed before treatment. A total of 52 patients with stageIII NPC and 64 patients with stageIV(AB) were planned to be enrolled.
Exclusion criteria included: pathology types that were not WHO II/III NPC; distant metastasis discovered by clinical or imaging examination; previous radiotherapy to the head and neck region; previous surgery in the primary tumor site or neck, except for diagnostic biopsy; history of malignant tumors or simultaneous multiple tumors, except for basal cell carcinoma of the skin; a positive pregnancy test result for women of reproductive age; accompanying disease or status influencing the normal enrollment of patients or safety during the research; active mental disorders or other mental disorders that influenced the patient爷s signature on the informed consent or comprehensibility; uncontrolled active infections; and participation in other clinical research at the same time.
Patients received radiotherapy by threedimensional conformal (3DCRT) or intensity modulated radiotherapy (IMRT) techniques. Gross tumor volume (GTV) referred to tumor extent found in clinical and imaging examinations, including primary tumor (GTVP) and metastatic lymph nodes (GTVN). To ensure that the pterygomaxillary fossa and areas of lymph node drainage of the upper neck (retropharyngeal lymph nodes and levels II, III, and Va) were included, clinical target volume (CTV) consisted of a certain margin surrounding the GTV, the whole nasopharynx cavity, the anterior one to twothirds of the clivus (when invaded, the whole clivus should be covered), the skull base, the pterygoid plates, the parapharyngeal space, the inferior sphenoid sinus (the whole sphenoid sinus should be covered for stages T3 and T4), the posterior onequarter to onethird of the nasal cavity and the maxillary sinus. Level Ib was at high risk in patients with metastatic lymph nodes in level IIa, and any lymph node drainage pathways containing metastatic lymph nodes were at high risk. Lowrisk CTV referred to levels IV and Vb without metastatic cervical lymph nodes.
In 3DCRT, highrisk GTVP, GTVN, and CTV were given a radiation dose of 60 Gy/30 fractions, followed by 1014 Gy/57 fractions to GTVP and 610 Gy/35 fractions to GTVN. Due to the shortage of machine resources, most of the patients receiving IMRT used a simplified IMRT technique to shorten the radiation time in each fraction, with prescription doses of 70 Gy, 66.5/68.25 Gy, and 61.25 Gy (in 35 fractions) for highrisk GTVP, GTVN, and CTV, respectively. Part of the patients were given boost irradiation doses of 46 Gy/23 fractions to the residual focus in the nasopharynx or the neck. CTV at low risk was radiated by 54 Gy/30 fractions in the anteriorposterior fields.
All patients received neoadjuvant chemotherapy before radiotherapy with the TPF regimen [docetaxel 75 mg/m 2 , day 1; cisplatin 75 mg/m 2 , day 1; 5Fu 500 mg/ 渊m 2 窑day冤, continuous intravenous infusion (CIV) for 120 h], every 3 weeks for 3 cycles. Dose titration of the neoadjuvant chemotherapy was the following. Complete blood count, liver function, and renal function were tested before each chemotherapy course, and only patients with a qualifying index (see enrollment criteria) could proceed with the next chemotherapy course. Chemotherapy was postponed in patients with hematologic index disqualification. The dosage of docetaxel was decreased by 20% with constant cisplatin and 5Fu dosages if a grade IV hematology adverse event or febrile neutropenia emerged in the former course. All of the dosages of docetaxel, cisplatin, and 5Fu were decreased by 20% if more than grade III mucositis or diarrhea happened in the former course. Concurrent chemoradiotherapy would be given after 3 courses of neoadjuvant chemotherapy as planned.
Concurrent chemotherapy consisted of weekly cisplatin (40 mg/m 2 ) during radiotherapy, with a maximum of 7 courses. Dose adjustments of concurrent chemotherapy went as follows. Complete blood count and serum biochemistry were tested before each course of chemotherapy, and only patients with a qualifying index (see enrollment criteria) could proceed with next course. Chemotherapy at the full dose would be delivered strictly according to the treatment protocol, and no adjustment would be allowed under any situation. The chemotherapy time could be postponed if neutropil < 2 × 10 9 /L or platelets < 100 × 10 9 /L . Chemotherapy could be suspended if the creatinine clearance rate < 50 mL/min. Shortterm treatment outcomes were evaluated according to physical examinations and magnetic resonance imaging (MRI) of the head and neck after neoadjuvant chemotherapy and 3 months after radiotherapy. According to the Response Evaluation Criteria in Solid Tumors (RECIST), shortterm treatment outcomes were divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). Adverse events were evaluated according to the latest version of the National Cancer Institute爷s Common Terminology Criteria for Adverse Events (NCI CTCAE 3.0). SPSS16.0 was used for statistical analysis. Descriptive statistics were used in summarizing the safety analysis. Survival rates were calculated with the KaplanMeier method. Each observation index was calculated from the commencement date of the cancer treatment.
This study analyzed 59 patients who were followed for 3 months. The median followup time was 14.3 months (3.124.6 months). The median age was 44 years (2169 years). The study included 46 men (78% ) and 13 women (22% ). The number of patients with stageIII and stageIV(AB) disease were 30 (50.8%) and 29 (49.2%), respectively.
The effectiveness of neoadjuvant chemotherapy to the primary tumor and cervical lymph nodes were 94.9% (CR rate was 25.4% ) and 100% (CR rate was 19.6% ), respectively. Shortterm treatment outcomes were evaluated 3 months after treatment, and the efficacy and the CR rate of the primary tumor rose to 100% and 96.6% , respectively, with the CR rate of cervical lymph nodes rising to 90.2% (Table 1) . Treatment failure was observed in 5 patients during followup, including 1 patient with lymph node relapse alone, 2 patients with distant metastasis alone, 1 patient with primary tumor and cervical lymph node relapse, and 1 patient with cervical lymph node relapse and distant metastasis. Two patients died. The rates of 1year overall survival (Figure 1 ), distant metastasisfree survival, and locoregional relapsefree survival were 100% , 95.7% , and 97.7%, respectively.
All patients completed at least 2 courses neoadjuvant Figure 1 Overall survival rate of patients with NPC chemotherapy, and 51 (86.4% ) patients completed 3 courses. Chemotherapy dosage was decreased in 14 (23.7% ) patients due to adverse events, including 12 patients in the second course and 2 in the third course. The median course of concurrent chemotherapy was 5 (17 courses). The number of patients who finished at least 5 or 4 courses of concurrent chemotherapy totaled 39 (66.1% ) and 50 (84.7% ), respectively. The incidence of severe bone marrow suppression and gastrointestinal reactions during neoadjuvant chemotherapy was 55.9% and 16.9% , respectively. The incidence of severe bone marrow suppression and gastrointestinal reaction during concurrent chemotherapy was 11.9% and 23.7% , respectively, while the incidence of severe radiation dermatitis, mucositis, and xerostomia were 6.8% , 44.1% , and 27.1% , respectively. No severe liver or renal function damage was observed. No treatmentrelated deaths occurred. Treatmentrelated adverse events are detailed in Table 2 During neoadjuvant chemotherapy acute adverse events ratio (%) During CCRT acute adverse events ratio (%) Event unsatisfactory, with the 5year survival rate around 35% for patients with stageIV (A B) disease (AJCC staging criteria, 1997) [1012] . NPC cells are sensitive to chemotherapy. As a result, oncologists have tried to combine chemotherapy to improve treatment outcomes for patients with locoregionally advanced NPC. After years of research, CCRT has recently become the standard treatment for patients with locoregionally advanced NPC [16] . For NPC patients with advanced N stages, especially those with metastatic lymph nodes in level IV, the risk of distant metastasis after treatment is far higher than locoregional relapse. Neoadjuvant chemotherapy is an effective way to control subclinical metastatic foci, and may be of great help in reducing the rate of distant metastasis, and hence improving overall survival. In patients with local large tumors or tumors close to critical normal tissue such as the brain stem, it is usually hard to deliver radiotherapy directly, and delivering full doses of radiation to tumors is always restricted by surrounding normal tissue. If tumors could shrink after neoadjuvant chemotherapy, it would benefit the design and delivery of radiotherapy.
However, compared to concurrent chemotherapy, phase III clinical trials have failed to prove that radiotherapy combined with neoadjuvant chemotherapy could improve the survival rate of patients with NPC with locoregionally advanced disease compared with radiotherapy alone [1315] . However, metaanalyses have shown that combined neoadjuvant chemotherapy could significantly reduce the risks of locoregional relapse (RR, 0.74; 95% CI, 0.600.91; = 0.005) and distant metastasis (RR, 0.67; 95% CI, 0.540.83; = 0.0003) [16] . Recently, Chua .
[17] conducted a pooled analysis for 2 randomized clinical trials that were similarly designed on neoadjuvant chemotherapy for patients with NPC. They collected data of 784 enrolled patients, reconstructed the database, and updated the followup results. The results showed that combined neoadjuvant chemotherapy brought down the rates of locoregional relapse ( = 0.037) and distant metastasis ( = 0.088), and significantly improved the rates of 5year relapsefree survival (50.9% vs. 42.7% , = 0.014) and diseaseassociated survival (63.5% vs. 58.1% , = 0.029). Nevertheless, there was not any improvement in overall survival, with 5year survival being 61.9% and 58.1%, and 7year survival being 57.2% and 48% , respectively. Neoadjuvant chemotherapy could reduce the risk of locoregional relapse and distant metastasis, but this could not be converted to the improvement of overall survival. Insufficient intensity and effectiveness of the chemotherapy agents or insufficient intensity of the local treatment might be the cause. As a result, changing to neoadjuvant chemotherapy regimens based on taxanes combined with CCRT might improve treatment outcomes. Various phase III clinical trials on other head and neck squamous cell carcinomas besides NPC have proven that TPF was significantly better than traditional PF regimens [79] . In recent years, various phase II clinical trials have been conducted with patients with locoregionally advanced NPC to evaluate treatment efficacy of neoadjuvant chemotherapy combined with CCRT. All of them showed encouraging results, and the 3year survival rates reached more than 70% [1823] . The phase II randomized clinical trial reported by Hui .
[23] from Hong Kong was the most representative one. Sixtyfive patients with NPC were enrolled on this clinical trial and were randomly assigned to receive CCRT alone (the control group) or neoadjuvant chemotherapy combined with CCRT (the study group). Neoadjuvant chemotherapy with the TPF regimen was as follows: docetaxel 75 mg/m 2 , day 1; cisplatin 75 mg/m 2 , day 1, every 3 weeks for 2 cycles. The concurrent chemotherapy was as follows: weekly cisplatin 40 mg/m 2 concurrent with radiotherapy. Statistical results indicated that the rate of 3year survival was significantly higher in the study group compared with the control group (94.1% vs. 67.7% , = 0.012). Our study adopted TPF as the neoadjuvant chemotherapy regimen combined with CCRT for patients with locoregionally advanced NPC, and also achieved good shortterm treatment results. Its longterm outcome still awaits further followup to be confirmed.
The most common adverse events during neoadjuvant chemotherapy based on taxanes was neutropenia, and the incidence of severe neutropenia was 37 % 97 % , whereas the incidence of febrile neutropenia was only 5.2%12.0% [79, 23] . Although neoadjuvant chemotherapy with higher treatment intensities were used, it seems that no significantly increased adverse events were observed during CCRT. In the study by Hui .
[23] , incidence of adverse events such as severe neutropenia (15.3% vs. 26.4%, = 0.30) and mucocitis (7.7% vs. 23.5%, = 0.11) in the control and study groups were similar. In the present study, patients showed good tolerance and compliance to the TPF neoadjuvant chemotherapy combined with CCRT. All the patients finished at least 2 courses of neoadjuvant chemotherapy, including 51 (86.4% ) patients who completed 3 courses. All patients received radiotherapy as planned, and 66.1% and 84.7% completed at least 5 or 4 courses concurrent chemotherapy, respectively. The incidence of severe neutropenia and febrile neutropenia caused by the TPF regimen was 52.5% and 20.3%, respectively, which was lower than those reported by Vermorken and Posner [8, 9] . This might due to the relatively lower dose of 5Fu in our study. The incidence of severe neutropenia, radiation dermatitis, and mucocitis was 1.7% , 6.8%, and 44.1% , respectively. No treatment related death occurred.
The results of our study indicated that TPF as a neoadjuvant chemotherapy regimen combined with CCRT for patients with locoregionally advanced NPC had tolerable adverse events, good compliance, and satisfying shortterm treatment efficacy. Confirming its longterm outcome awaits further followup. The taxanebased TPF neoadjuvant chemotherapy regimen combined with CCRT is worth further research in the patients with locoregionally advanced NPC.
